HCP

LACTOBACILLUS ACIDOPHILUS

La-14®

Grant JR, Stothard P. The CGView Server: a comparative genomics tool for circular genomes. Nucleic Acids Res. 2008;36:W181-W184.

La-14® Introduction

L acidophilus La-14® is a lactic acid bacterium of human origin that has been documented in over 50 scientific studies, including 18 clinical trials.  Preclinical studies have shown La-14® can impact both the innate and adaptive immune system.1,2  These effects and antipathogenic activity are thought to be potential mechanisms behind the efficacy of La-14® combined with HN001™ in women’s health.3,4 In addition, these two strains together have been shown to support healthy vaginal colonization through oral supplementation.5

37 In vitro through product functionality studies

+17

Clinical trials

HEALTH-BENEFIT AREA SUPPORTED DOSING (CFU) STUDY REFERENCE
Women’s Health (Vaginal colonization)  10 billion La-14®, HN001™, lactoferrin De Alberti D, et al. Arch Gynecol Obstet. 2015;292(4):861-867.
Women’s Health (Vaginitis/vaginosis)  5 billion La-14®, HN001™, with 50 mg of bovine lactoferrin RCX™ Russo R, et al. Arch Gynecol Obstet. 2018;298(1):139-145.
Women’s Health (Bacterial vaginosis)  5-10 billion La-14®, HN001™, lactoferrin in patients being treated with metronidazole (500 mg twice daily) Russo R, et al. Benef Microbes. 2019;10(1):19-26.
Women’s Health (Vulvovaginal candidiasis) 5-10 billion La-14®, HN001™, lactoferrin in patients being treated with topical clotrimazole (100 mg) Russo R, et al. Mycoses. 2018;62(4):328-335.

For additional information, visit our La-14® bibliography

REFERENCES:
1. Elawadli I, Brisbin JT, Mallard BA, et al. Differential effects of lactobacilli on activation and maturation of mouse dendritic cells. Beneficial Microbes. 2014;5(3):323-334. 2. Paineau D, Carcano D, Leyer G. Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial. FEMS Immunol Med Microbiol. 2008;53(1):107-113. 3. Bertuccini L, Russo R, Iosi F, Superti F. Effects of Lactobacillus rhamnosus and Lactobacillus acidophilus on bacterial vaginal pathogens. Intl J Immunopathology Pharmacology. 2017;30(2):163-167. 4. Jang SE, Jeong JJ, Choi SY, et al. Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14 attenuate gardnerella vaginalis-infected bacterial vaginosis in mice. Nutrients. 2017;9:531; doi:10.3390/nu9060531. 5. De Alberti D, Russo R, Terruzzi F, Nobile V, Ouwehand AC. Lactobacilli vaginal colonisation after oral consumption of Respecta® complex: a randomized controlled pilot study. Arch Gynecol Obstet. 2015;292(4):861-867.
The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.
ARE YOU A HEALTHCARE PROFESSIONAL?
YES
NO